JP2019534286A - 放射エネルギーによる崩壊の標的とされる癌結合性有色ペプチド - Google Patents

放射エネルギーによる崩壊の標的とされる癌結合性有色ペプチド Download PDF

Info

Publication number
JP2019534286A
JP2019534286A JP2019522672A JP2019522672A JP2019534286A JP 2019534286 A JP2019534286 A JP 2019534286A JP 2019522672 A JP2019522672 A JP 2019522672A JP 2019522672 A JP2019522672 A JP 2019522672A JP 2019534286 A JP2019534286 A JP 2019534286A
Authority
JP
Japan
Prior art keywords
radiant energy
peptide
light
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019522672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534286A5 (enExample
Inventor
ジェンセン、スティーブン、ディー．
Original Assignee
カオ グループ、インク．
カオ グループ、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カオ グループ、インク．, カオ グループ、インク． filed Critical カオ グループ、インク．
Publication of JP2019534286A publication Critical patent/JP2019534286A/ja
Publication of JP2019534286A5 publication Critical patent/JP2019534286A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2019522672A 2016-10-26 2017-10-25 放射エネルギーによる崩壊の標的とされる癌結合性有色ペプチド Pending JP2019534286A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662412938P 2016-10-26 2016-10-26
US62/412,938 2016-10-26
PCT/US2017/058267 WO2018081254A1 (en) 2016-10-26 2017-10-25 Cancer binding chromatic peptides that are targeted for disintegration by radiant energy

Publications (2)

Publication Number Publication Date
JP2019534286A true JP2019534286A (ja) 2019-11-28
JP2019534286A5 JP2019534286A5 (enExample) 2020-10-08

Family

ID=62025444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522672A Pending JP2019534286A (ja) 2016-10-26 2017-10-25 放射エネルギーによる崩壊の標的とされる癌結合性有色ペプチド

Country Status (4)

Country Link
US (1) US20190275173A1 (enExample)
JP (1) JP2019534286A (enExample)
CN (1) CN109963874A (enExample)
WO (1) WO2018081254A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7090958B2 (ja) * 2018-06-01 2022-06-27 アドレイ・ノーティ・バイオファーマ・カンパニー・リミテッド 高活性ｃｓｆ１ｒ阻害薬化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160015829A1 (en) * 2010-07-09 2016-01-21 The Usa As Represented By The Secretary, Department Of Health And Human Services Photosensitizing antibody-fluorophore conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8180436B2 (en) * 2006-04-12 2012-05-15 The Invention Science Fund I, Llc Systems for autofluorescent imaging and target ablation
WO2009045579A2 (en) * 2007-06-14 2009-04-09 The Regents Of The University Of California Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics
AU2013383382B2 (en) * 2013-03-15 2017-02-23 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160015829A1 (en) * 2010-07-09 2016-01-21 The Usa As Represented By The Secretary, Department Of Health And Human Services Photosensitizing antibody-fluorophore conjugates

Also Published As

Publication number Publication date
US20190275173A1 (en) 2019-09-12
WO2018081254A1 (en) 2018-05-03
CN109963874A (zh) 2019-07-02

Similar Documents

Publication Publication Date Title
Khalkhal et al. The evaluation of laser application in surgery: a review article
Bown Photodynamic therapy for photochemists
US20100305436A1 (en) Systems, devices, and methods for photoactive assisted resection
Dougherty Photodynamic therapy—new approaches
Allison et al. Photodynamic therapy (PDT) for lung cancer
Cortese et al. Endoscopic management of lung cancer with hematoporphyrin derivative phototherapy
US9550072B2 (en) Diagnostic device, therapeutic device, and uses thereof
US20120041305A1 (en) Light-emitting dye for intraoperative imaging or sentinel lymph node biopsy
KR20090094331A (ko) 광선 역학적 치료(ｐｄｔ)를 이용한 이상 전기 전도 차단 장치
Pope et al. Photodynamic
Barr et al. Local eradication of rat colon cancer with photodynamic therapy: correlation of distribution of photosensitiser with biological effects in normal and tumour tissue.
Cortese et al. Hematoporphyrin-derivative phototherapy for local treatment of cancer of the tracheobronchial tree
Smith et al. Experimental studies to assess the potential of photodynamic therapy for the treatment of bronchial carcinomas.
US20190275173A1 (en) Cancer binding chromatic peptides that are targeted for disintegration by radiant energy
WO2019244977A1 (ja) 腫瘍治療法
Liu et al. High‐power 450 nm blue diode laser for endoscopic mucosal resection/endoscopic submucosal dissection in the stomach: Preliminary results on a porcine model with a modified flexible endoscope
Gossner et al. Photodynamic therapy of gastric cancer
CN209361672U (zh) 一种可激发自体荧光的激光前列腺治疗系统
JP2019534285A (ja) 放射エネルギーによる崩壊の標的とされる癌結合性放射線不透過性ペプチド
Saidi et al. Nonthermal ablation of malignant esophageal strictures: photodynamic therapy, endoscopic intratumoral injections, and novel modalities
Kawaguchi et al. Two different methods of bronchial dissection and coverage in robotic bilobectomy for advanced lung cancer
US20130035684A1 (en) Laser Treatment of Tissues at Wavelengths above 1330 nm
Belmont et al. Effect of photodynamic therapy on revascularization of fasciocutaneous flaps
Brunetaud et al. Lasers in digestive endoscopy
US20060282133A1 (en) Method of Marking Biological Tissues for Enhanced Destruction by Applied Radiant Energy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220308